Predicting glioblastoma response to bevacizumab through marker profiling?
نویسنده
چکیده
منابع مشابه
Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme
Glioblastoma multiforme (GBM) possesses florid angiogenesis. However, the anti-angiogenic agent, Bevacizumab, did not improve overall survival of GBM patients. For more durable anti-angiogenic treatment, we interrogated resistant mechanisms of GBM against Bevacizumab. Serial orthotopic transplantation of in vivo Bevacizumab-treated GBM cells provoked complete refractoriness to the anti-angiogen...
متن کاملEvidence for rCBV as an early response marker following bevacizumab treatment.
I appreciate the thoughtful letter from Schmainda et al. regarding the utility of rCBV derived from MRI as a biomarker of response to bevacizumab therapy in patients with recurrent glioblastoma (GBM). The authors cite their recent work in which they found that tumoral rCBV changes were predictive of overall survival at 2 and 16 weeks, but not 8 weeks, after the start of bevacizumab therapy in p...
متن کاملBevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.
Therapy-induced calcifications in glioblastoma are rarely recognized. They may represent regressive changes in the tumor tissue, but their occurrence and possible predictive or prognostic value have not been systematically assessed. The observation of hyperintense lesions on precontrast T1-weighted magnetic resonance images (MRIs) in 2 index patients with glioblastoma after therapy with bevaciz...
متن کاملAngiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.
BACKGROUND Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients. METHODS The study included a total of 82 recurr...
متن کاملPhase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of vorinostat with bevacizumab and CPT-11 in recurrent glioblastoma. Vorinostat was combined with bevacizumab and CPT-11 and was escalated using a standard 3 + 3 design. Vorinostat was escalated up to 2 actively investigated doses of this compound or until the MTD w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Neuro-oncology
دوره 18 2 شماره
صفحات -
تاریخ انتشار 2016